Home › Cancro ai polmoni › Illinois › Waukegan
Studi clinici su Cancro ai polmoni a Waukegan, IL
16 studi su Cancro ai polmoni cercano partecipanti presso sedi a Waukegan e dintorni (entro circa 30 miglia). Apri uno studio per vedere chi può partecipare e come contattare il team.
Testo ufficiale dello studio (inglese)
Stai reclutando per uno studio? Mettilo in evidenza in cima alla pagina — $99 per 30 giorni →
Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial
In reclutamentoFase 3
- AMG Libertyville - Oncology, Libertyville · a 8 mi di distanza
- Condell Memorial Hospital, Libertyville · a 8 mi di distanza
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
In reclutamentoFase 3
- AMG Libertyville - Oncology, Libertyville · a 8 mi di distanza
- Condell Memorial Hospital, Libertyville · a 8 mi di distanza
Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer
In reclutamentoFase 3
- Northwestern Medicine Lake Forest Hospital, Lake Forest · a 7 mi di distanza
- Northwestern Medicine Grayslake Outpatient Center, Grayslake · a 10 mi di distanza
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
In reclutamentoStudio osservazionaleVolontari sani benvenuti
- AMG Libertyville - Oncology, Libertyville · a 8 mi di distanza
- Condell Memorial Hospital, Libertyville · a 8 mi di distanza
Empathic Communication Skills (ECS) Training
In reclutamentoVolontari sani benvenuti
- Advocate Health Care Network, Libertyville · a 8 mi di distanza
Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
In reclutamentoFase 3
- Northwestern Medicine Lake Forest Hospital, Lake Forest · a 7 mi di distanza
- Northwestern Medicine Grayslake Outpatient Center, Grayslake · a 10 mi di distanza
This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.
In reclutamentoFase 3
- Advocate Medical Group - Libertyville Oncology, Libertyville · a 8 mi di distanza
Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
In reclutamentoFase 1
- City of Hope - Chicago, Zion · a 6 mi di distanza
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
In reclutamentoFase 3
- City of Hope® Cancer Center Chicago, Zion · a 6 mi di distanza
Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer
In reclutamentoFase 3
- Midwestern Regional Medical Center, Zion · a 6 mi di distanza
- AMG Libertyville - Oncology, Libertyville · a 8 mi di distanza
- Condell Memorial Hospital, Libertyville · a 8 mi di distanza
Evaluate the Clinical Performance of the Flow Cytometry - FlowPath Lung Test as a Sensitive and Specific Non-invasive Diagnostic of Sputum Samples to Identify/Detect the Presence of Lung Cancer in High-risk Individuals Who Have Existing Lung Nodules, 6 to <30 mm in Diameter, Determined by LDCT.
In reclutamento
- Captain James A. Lovell Federal Health Care Center, North Chicago · a 3 mi di distanza
Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
In reclutamentoFase 2
- Northwestern Medicine Lake Forest Hospital, Lake Forest · a 7 mi di distanza
- AMG Libertyville - Oncology, Libertyville · a 8 mi di distanza
- Condell Memorial Hospital, Libertyville · a 8 mi di distanza
- e altri 1
Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
In reclutamentoFase 2/3
- Northwestern Medicine Lake Forest Hospital, Lake Forest · a 7 mi di distanza
- AMG Libertyville - Oncology, Libertyville · a 8 mi di distanza
- Condell Memorial Hospital, Libertyville · a 8 mi di distanza
- e altri 1
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)
In reclutamentoFase 2
- Northwestern Medicine Lake Forest Hospital, Lake Forest · a 7 mi di distanza
- Northwestern Medicine Grayslake Outpatient Center, Grayslake · a 10 mi di distanza
Immunotherapy Biomarkers to Predict First-line PD(L)1-based Immunotherapy Response and Selection of Second-line Treatment in Stage IIIB-IV Non-small Cell Lung Cancer, IMMUNO-BIOMAP Trial
In reclutamentoFase 2
- City of Hope at Chicago, Zion · a 6 mi di distanza
LOTUS-CC: An Observational Research Study to Uncover Subtypes of Cancer Cachexia
In reclutamentoStudio osservazionale
- AMG Libertyville - Oncology, Libertyville · a 8 mi di distanza
- Condell Memorial Hospital, Libertyville · a 8 mi di distanza
Studi su Cancro ai polmoni in altre città
- Houston, TX78 studi
- Boston, MA62 studi
- New York City, NY60 studi
- Los Angeles, CA45 studi
- Arlington, VA41 studi
- Washington, DC41 studi
- Chicago, IL41 studi
- Baltimore, MD40 studi
- Nashville, TN40 studi
- St. Louis, MO39 studi
- Columbus, OH37 studi
- Philadelphia, PA36 studi
Altri studi a Waukegan
- Cancro del polmone non a piccole cellule16 studi
- Cancro al seno12 studi
- Colite ulcerosa7 studi
- Cancro al rene (carcinoma a cellule renali)7 studi
- Cancro ovarico6 studi
- Cancro metastatico6 studi
- Carcinoma a cellule squamose della testa e del collo6 studi
- Cancro colorettale6 studi
- Cancro alla prostata6 studi
- Melanoma5 studi
- Leucemia mieloide acuta5 studi
- Malattia di Crohn5 studi
Fonte: ClinicalTrials.gov, dati recuperati il 6 ott 2026. Ogni studio stabilisce i propri criteri di idoneità; è il team di ricerca a decidere chi può partecipare.